Tscan Therapeutics Q3 2024 Earnings Report
Key Takeaways
TScan Therapeutics reported third quarter 2024 financial results, with revenue at $1.0 million compared to $3.9 million for the same period in 2023. Net loss was $29.9 million, compared to $23.0 million for the third quarter of 2023. Cash, cash equivalents, and marketable securities totaled $271.1 million, expected to fund operations into the fourth quarter of 2026.
Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
Company to host virtual KOL event on December 10th to discuss clinical updates from the ALLOHA Phase 1 trial and heme development strategy.
On track to dose first patient with multiplex TCR-T therapy and will provide an update on our Phase 1 study by the end of the year.
Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026.
Tscan Therapeutics
Tscan Therapeutics
Tscan Therapeutics Revenue by Segment
Forward Guidance
TScan Therapeutics plans to open expansion cohorts at the proposed recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints by the end of 2024. One-year clinical and translational data on initial patients to be reported by the end of 2024. Initiate a registration trial, pending feedback from regulatory authorities, and plans to report two-year clinical and translational data in 2025. Update on solid tumor program expected by the end of 2024. Investigational new drug (IND) filing for TCR targeting MAGE-A4 on HLA-A*02:01 (TSC-202-A0201) planned by the end of the year. Response data for multiplex therapy anticipated in 2025.
Positive Outlook
- Plans to open expansion cohorts at the proposed recommended Phase 2 dose level to further characterize safety and evaluate translational and efficacy endpoints by the end of 2024.
- One-year clinical and translational data on initial patients to be reported by the end of 2024.
- Initiate a registration trial, pending feedback from regulatory authorities, and plans to report two-year clinical and translational data in 2025.
- Update on solid tumor program expected by the end of 2024.
- Investigational new drug (IND) filing for TCR targeting MAGE-A4 on HLA-A*02:01 (TSC-202-A0201) planned by the end of the year.